Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH

Eric L. Allen(Agios Pharmaceuticals (United States)), Danielle Ulanet(Agios Pharmaceuticals (United States)), David Pirman(Agios Pharmaceuticals (United States)), Christopher E. Mahoney(Agios Pharmaceuticals (United States)), John Coco(Agios Pharmaceuticals (United States)), Yaguang Si(Agios Pharmaceuticals (United States)), Ying Chen, Lingling Huang, Jinmin Ren, Sung Choe(Agios Pharmaceuticals (United States)), Michelle Clasquin(Agios Pharmaceuticals (United States)), Erin Artin(Agios Pharmaceuticals (United States)), Zi Peng Fan(Agios Pharmaceuticals (United States)), Giovanni Cianchetta(Agios Pharmaceuticals (United States)), Joshua Murtie(Agios Pharmaceuticals (United States)), Marion Dorsch(Agios Pharmaceuticals (United States)), Shengfang Jin(Agios Pharmaceuticals (United States)), Gromoslaw A. Smolen(Agios Pharmaceuticals (United States))
Cell Reports
October 1, 2016
Cited by 69Open Access
Full Text

Abstract

Although aberrant metabolism in tumors has been well described, the identification of cancer subsets with particular metabolic vulnerabilities has remained challenging. Here, we conducted an siRNA screen focusing on enzymes involved in the tricarboxylic acid (TCA) cycle and uncovered a striking range of cancer cell dependencies on OGDH, the E1 subunit of the alpha-ketoglutarate dehydrogenase complex. Using an integrative metabolomics approach, we identified differential aspartate utilization, via the malate-aspartate shuttle, as a predictor of whether OGDH is required for proliferation in 3D culture assays and for the growth of xenograft tumors. These findings highlight an anaplerotic role of aspartate and, more broadly, suggest that differential nutrient utilization patterns can identify subsets of cancers with distinct metabolic dependencies for potential pharmacological intervention.


Related Papers

No related papers found

Powered by citation graph analysis